GB2497216B - A method of increasing the sensitivity of a cell to DNA double strand damage in vitro and inhibitors of H1x function - Google Patents

A method of increasing the sensitivity of a cell to DNA double strand damage in vitro and inhibitors of H1x function

Info

Publication number
GB2497216B
GB2497216B GB1301168.9A GB201301168A GB2497216B GB 2497216 B GB2497216 B GB 2497216B GB 201301168 A GB201301168 A GB 201301168A GB 2497216 B GB2497216 B GB 2497216B
Authority
GB
United Kingdom
Prior art keywords
vitro
inhibitors
sensitivity
cell
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1301168.9A
Other versions
GB2497216A (en
GB201301168D0 (en
Inventor
Boris Kysela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB201301168D0 publication Critical patent/GB201301168D0/en
Publication of GB2497216A publication Critical patent/GB2497216A/en
Application granted granted Critical
Publication of GB2497216B publication Critical patent/GB2497216B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
GB1301168.9A 2010-06-23 2011-06-23 A method of increasing the sensitivity of a cell to DNA double strand damage in vitro and inhibitors of H1x function Expired - Fee Related GB2497216B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1010588.0A GB201010588D0 (en) 2010-06-23 2010-06-23 Cancer treatment
PCT/GB2011/051180 WO2011161457A1 (en) 2010-06-23 2011-06-23 Cancer treatment

Publications (3)

Publication Number Publication Date
GB201301168D0 GB201301168D0 (en) 2013-03-06
GB2497216A GB2497216A (en) 2013-06-05
GB2497216B true GB2497216B (en) 2015-11-11

Family

ID=42582889

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1010588.0A Ceased GB201010588D0 (en) 2010-06-23 2010-06-23 Cancer treatment
GB1301168.9A Expired - Fee Related GB2497216B (en) 2010-06-23 2011-06-23 A method of increasing the sensitivity of a cell to DNA double strand damage in vitro and inhibitors of H1x function

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB1010588.0A Ceased GB201010588D0 (en) 2010-06-23 2010-06-23 Cancer treatment

Country Status (2)

Country Link
GB (2) GB201010588D0 (en)
WO (1) WO2011161457A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507225A (en) 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Delivery system using mab 3E10 and mutant and / or functional fragments thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BMC CANCER, vol. 8, no. 1, 2008, Warneboldt et al. "Histone H1x is highly expressed in human neuroendocrine cells and tumours", 388 *
Cell Cycle (2010); Vol 9, pp 662-669, "[gamma]H2AX foci analysis...", Loebrich et al *
DNA Repair (2007); Vol 6, pp 1584-1595, "Histone H1 variant, H1R is involved in DNA damage response", Hashimoto et al *
FEBS Letters (2007); Vol 581, pp 3422-3428, "Proapoptotic histone H1.2 induces CASP-3...", Ruiz-Vela & Korsmeyer *
FEBS Letters (2007); Vol 581, pp 3783-3788, "H1.X with different properties...", Takata et al *
FEBS LETTERS, vol. 581, no. 20, 2007, Takata et al. "H1.X with different properties from other linker histones is required for mitotic progression", pages 3783-3788 *
Journal of Cell Science, vol. 115, no. 14, 2002, Jedrusik et al. "A novel linker histone-like protein is associated with cytoplasmic filaments in Caenorhabditis elegans", pages 2881-2891 *
Molecular Cell (2003); Vol 11, pp 1685-1692, "Suppression of homologous recombination...", Downs et al *

Also Published As

Publication number Publication date
GB2497216A (en) 2013-06-05
GB201010588D0 (en) 2010-08-11
GB201301168D0 (en) 2013-03-06
WO2011161457A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
EP2391711A4 (en) Novel cell lines and methods
EP2416792A4 (en) Novel anti-aging agents and methods to identify them
GB2488918B (en) Sugar mixtures and methods for production and use thereof
EP2648261A4 (en) Method for manufacturing battery cell and battery cell produced using same
ZA201209558B (en) Rechargeable battery and method
PT2683815E (en) Genetically modified cell and process for use of said cell
EP2620964A4 (en) Energy storage device and energy storage device production method
EP2479250A4 (en) Biodiesel and preparation method thereof
EP2393930A4 (en) Cell lines expressing cftr and methods of using them
SG10201405455UA (en) Cells and methods for obtaining them
EP2407556A4 (en) Method for determining sensitivity to irinotecan and use thereof
EP2725097A4 (en) Cell culture device and cell culture method
EP2700707A4 (en) Cell culture method and cell culture kit
EP2632931A4 (en) Compositions and methods for specific cleavage of exogenous rna in a cell
GB201113641D0 (en) Cell culture support and cell culture method
EP2591355A4 (en) In vitro point-of-care sensor and method of use
GB201014335D0 (en) Improvements in and relating to analysis
ZA201207761B (en) Method for inhibiting hiv replication in mammal and human cells
EP2391710A4 (en) Cell lines expressing guanylate cyclase-c and methods of using them
EP2569441A4 (en) Kit and method
EP2578603A4 (en) B cell activating factor antagonist and preparation method and use thereof
GB2497216B (en) A method of increasing the sensitivity of a cell to DNA double strand damage in vitro and inhibitors of H1x function
EP2711382A4 (en) Difluoro benzotriazolyl solar cell material and preparation method and use thereof
GB201111040D0 (en) Improved solar still and method of use thereof
EP2605916A4 (en) Calendar and calendar production methods

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20150716 AND 20150722

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20160211